A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.

doi:10.1016/j.bbmt.2014.03.022

Article

A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation - 1 Jul 2014

Giglia Jennifer L, White Marquitta J, Hart Andrew J, Toro Juan J, Freytes César O, Holt Cherish C, Cai Ying, Williams Scott M, Brandt Stephen J

Abstract excerpt

Multiple myeloma is the most frequent indication for high-dose melphalan (HDM) chemotherapy with autologous stem cell transplantation (ASCT). Gastrointestinal symptoms represent the most significant nonhematological toxicity of HDM. However, specific, especially genetic, predictors of their incidence or clinical severity are lacking. The amino acid transporters LAT1 and LAT2 encoded by the SLC7A5 and SLC7A8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.

Abstract excerpt

Topics

Related research